Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
Breast Cancer · Gastric Cancer · Gastroesophageal Junction Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 71 (final count)
- Started
- Mar 23, 2020
- Main results expected
- Dec 7, 2023
- Fully finished
- Oct 31, 2024
- Results posted
- Sep 2, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 42 months
Objective Response Rate (ORR)
Measured over: Response was assessed every 6 weeks from cycle 1 day 1 for the first 36 weeks and then every 12 weeks thereafter; maximum time on study follow-up was 42months.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04276493 · record last updated 2026-09-02 · checked 2026-11-09 15:47 UTC